Collaboration Advances Preeclampsia Research in Low- and Middle-Income Countries
Sao Paulo, Brazil – October 24, 2016 – Last night at the opening ceremonies of the World Congress of the International Society for the Study of Hypertension in Pregnancy (ISSHP) in Brazil, the Preeclampsia Foundation, along with its partners ISSHP and the PRE-EMPT/Global Pregnancy Collaboration (CoLab), announced the recipient of their EMPOWER Award for preeclampsia-related research.
Dr. Sarah Manyame, a physician-researcher with the Department of Obstetrics and Gynaecology at the University of Zimbabwe Parirenvatwa Group of Hospitals, was awarded $60,000 USD for her two-year project “Urine Biomarkers for Preeclampsia in High Risk Women.” Dr. James Roberts with the Magee-Womens Research Institute in Pittsburgh, Pennsylvania, will serve as Dr. Manyame’s mentor.
EMPOWER (EMpowering Progress in Obstetric and Women’s hEalth Research) was established to create partnerships between mentors and medical researchers within low- and middle-income countries to improve clinical and health services research into hypertensive disorders of pregnancy. Ninety-nine percent of maternal deaths from preeclampsia occur in low-resource settings like Zimbabwe, where 35 percent of maternal mortality is due to preeclampsia and eclampsia.
“This is the second award granted to a preeclampsia researcher from a low- to middle-income country through EMPOWER,” said Eleni Tsigas, Executive Director of the Preeclampsia Foundation. “We’re pleased to continue this program, welcoming ISSHP, PRE-EMPT/CoLab, and supporting organization New Zealand Action on Pre-eclampsia.”
With the resource constraints facing the country, Dr. Manyame said, “Zimbabwe needs a readily available, simple non-invasive test for the prediction of preeclampsia and the severity of the outcomes. Thus, this study will evaluate the preeclampsia predictive value of the Congo red Dot test, protein/creatinine ratio, calcium/creatinine ratio, PlGF/soluble Flt-1 ratio, in women at high risk and at varying stages of the disease.”
The immediate objective will be the completion of the project designed by Dr. Manyame and, when appropriate, the dissemination of the results of the study to change practice and improve care. A fundamental goal of the program is to build independent capacity for research and effective local implementation of research findings. Other objectives include developing an integrated hypertension research team, advancing the knowledge base, and supporting research operations.
Preeclampsia, the most dangerous form of pregnancy hypertension, is estimated to contribute to at least 120 maternal and 1,300 fetal or newborn deaths every day throughout the world, primarily in regions such as the Indian subcontinent, Africa, and Latin America. Most of these cases are considered preventable.
Answers to our most frequently asked questions about the registry
Everyone can play a role in preeclampsia research. Enroll Today login
The Preeclampsia Registry is a valuable resource that you can turn to when posing new questions, testing new hypotheses, and building study cohorts. As a “living database” that i...
According to the World Health Organization, preeclampsia is one of the least funded areas of research, especially when considered against Disability Adjusted Life Years (DALYs). The Preeclampsia Found...
The Letter of Intent period is CLOSED for the 2020 Peter Joseph Pappas Research Grants funding program. Decisions will be rendered in December 2020 and the next funding round will be announced next ye...
Melbourne, FL – December 30, 2020 – The Preeclampsia Foundation announces the recipients of its 2021 Peter Joseph Pappas Research Grants, a funding program designed to accelerate p...
Title: Vitamin D in the womb may be protective for babies born from pregnancies complicated by preeclampsia Article Title: Associations of Cord Blood Vitamin D and Preeclampsia With Offspring B...
August 6, 2020 – Melbourne, FL – The Preeclampsia Foundation is seeking Letters of Intent for the Peter Joseph Pappas Research Grants funding program, designed to accelerate preeclampsia r...
TREATMENT Results of a trial to test a new medication for preterm preeclampsia: the PRESERVE-1 Trial AJOG Preterm preeclampsia is a rare form of preeclampsia that occurs at 23-30 weeks of...
LONG-TERM EFFECTS Adverse Pregnancy Outcomes and Long-term Maternal Kidney Disease: A Systematic Review and Meta-analysis JAMA Network Open Researchers sought to combine the available data to s...